Research programme: oral peptides - Sigmoid Pharma
Latest Information Update: 28 Oct 2016
At a glance
- Originator Sigmoid Pharma
- Class Peptides
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 17 Oct 2016 Preclinical trials in Undefined indication in Ireland (PO) before October 2016 (Sigmoid Pharma pipeline, October 2016)